Genistein is often used as an inhibitor of tyrosine kinases. A less studied side effect of genistein is an inhibition of cyclic AMPphosphodiesterase (cAMP-PDE) activity resulting in increased cAMP accumulation. The effect of genistein on intracellular cAMP-levels, basal and forskolin-induced, was studied in A549 human airway epithelial cells and compared with the unspecific PDE inhibitor, isobutylmethylxanthine (IBMX). It was shown that genistein (50 µM) increased basal cAMP and potentiated forskolin-induced cAMP accumulation to the same extent as IBMX (100 µM . In rat aortic rings, genistein was shown to potentiate β1-adrenoceptor-induced relaxation by inhibiting PDE activity [4] . Relaxation induced by forskolin, an activator of adenylyl cyclase [5] , was potentiated by genistein in the absence but not in the presence of the PDE inhibitor theophylline, indicating that genistein and theophylline were competing for the same target [4] .
Introduction
Intracellular signaling events are often studied by the use of inhibitors assumed to be selective. The isoflavone genistein is a potent inhibitor of tyrosine-specific protein kinase activity and acts as a competitive inhibitor to ATP [1] . However, genistein and other tyrosine kinase inhibitors competing with ATP have been shown to affect the activity of other nucleotidebinding proteins such as the hexose transporter GLUT 1 [2] . Only tyrosine kinase inhibitors with specificity for ATP binding sites but not those competitive with tyrosine were shown to directly inhibit the activity of GLUT 1, and the inhibition was instantaneous [2] .
Another example for inhibition by genistein of a nucleotide-binding protein is cyclic adenosine 3′,5′-monophosphate phosphodiesterase (cAMP-PDE). In a neural cell line, PDE activity was blocked in a tyrosine kinase-independent tion by treatment with genistein and the unspecific PDE inhibitor isobutylmethylxanthine (IBMX) was analyzed in A549 cells. In addition, the effects by pretreatment with genistein or IBMX on the accumulation of cAMP caused by forskolin were compared.
Material and methods

Chemicals
Genistein, forskolin and isobutylmethylxanthine (IBMX) were purchased from Sigma-Aldrich, Sweden.
Genistein and forskolin were first dissolved in dimethyl sulfoxide (DMSO) and subsequently diluted to working concentrations in Ham's F12 medium. The final concentration of DMSO never exceeded 0.01%, a concentration not affecting basal cAMP levels which was established in preliminary studies.
Cell culture
A human airway epithelial cell line, A549 (ATCC No. CCL-185) was used. The cells were cultured in Ham's F12 medium containing 10% foetal calf serum, supplemented with 1% penicillin/streptomycin and 1% L-glutamine (Ham's F12 complete medium) in a humidified atmosphere of 5% CO 2 / 95% air at 37°C.
Experimental conditions and measurement of cAMP accumulation
The A549 cells were seeded at 1.5 × 10 5 cells/well in 35 mm dishes (Nunc, Roskilde, Denmark) and grown in 2 ml Ham's F12 complete medium for 2 days. The medium was replaced with fresh medium and cultivation was continued for an additional 20 h. The near-confluent cells were washed twice in Ham's F12 (w/o FCS, w/o penicillin/streptomycin), preincubated for 20 min at 37°C (5% CO 2 /95% air mixture) in Ham's F12 with genistein (50 µM) followed by the addition of either F12 or F12 with forskolin to a final concentration of 10 µM, and the incubation was continued for an additional 30 min. To investigate the effect of forskolin alone, the cells were first incubated with Ham's F12 for 20 min, when forskolin was added to a final concentration of 10 µM and the incubation was continued for 30 min. To block PDE activity, the cells were incubated in Ham's F12 with IBMX (100 µM) for 20 min when either F12 or F12 with forskolin (to a final concentration of 10 µM) was added and the incubation was continued for an additional 30 min.
Basal level of cAMP was determined in cells incubated for 50 min in Ham's F12 with 0.01% DMSO.
The medium was aspirated and the cells were collected by scraping with a Cell Scraper (Nunc) and resuspended in ice cold EDTA (4 mM). Proteins were coagulated by boiling for 2 min. Following centrifugation at 10,000 × g for 10 min, cAMP was quantified in the supernatant by use of a radioreceptor assay system, Biotrak (Amersham Pharmacia Biotech, Sweden), according to manufacturer's instructions. The pellet was resuspended in water and protein content measured with BCA Protein Assay Kit (Pierce, Rockford, USA). cAMP concentrations were expressed as pmol cAMP/mg protein.
Statistical analysis
The experiments were performed twice in triplicate. Statistical analysis was performed by the use of Student's t-test for unpaired observations. A p value of <0.05 was considered significant. Table 1 shows that in the A549 cells the impact on cAMP levels by genistein at 50 µM equals that of the PDE inhibitor IBMX at 100 µM after the same incubation time (50 min). Furthermore, the two agents, genistein and IBMX, potentiated forskolin-induced accumulation of cAMP to similar extent. The increase was approximately 7-fold by pretreatment with genistein and approximately 5-fold by pretreatment with IBMX.
Results
Genistein at a concentration of 100 µM precipitated in the medium used in the present study. The effect by increased concentrations was therefore not tested. 
Discussion
Studies on intracellular signaling often include combined effect of various agents. In the present study, a combination of the tyrosine kinase inhibitor genistein and forskolin, an activator of adenylyl cyclase, resulted in a several-fold increase in intracellular cAMP levels compared with forskolin alone. Increased cAMP levels may result in increased gene expression. Transcriptional induction by cAMP is mediated by the CRE binding protein (CREB), which is phosphorylated and activated after translocation of the catalytic subunit of protein kinase A (PKA) to the nucleus [9] . In addition to its effect on protein synthesis, increased intracellular cAMP and the subsequent activation of PKA may influence other cellular functions such as receptor-G protein coupled signaling [10] , which in turn could alter the response to an activating agent. Genistein has also been used to investigate tyrosine kinase signaling in inflammation. In a study on signaling transductions induced by a bacterial toxin, pyocyanin, exposure of A549 epithelial cells to genistein (300 µM) for 24 h reduced basal IL-8 release by approximately 60% and the pyocyanininduced IL-8 release by approximately 85% [11] . Similar results were obtained in our laboratory with a lower dose of genistein. Thus, 24 h exposure to genistein (50 µM) decreased basal release of IL-8 by 60% and the increased release of IL-8 induced by exposure to organic dust from a swine confinement building by 90% in A549 cells (unpublished results). From the results of the present study, it can not be concluded that the effect by genistein in either of the studies mentioned above was caused by inhibition of tyrosine kinase activity, only. The inhibition of IL-8 release was most likely a consequence of genistein affecting several transduction pathways.
Genistein is commonly used to examine intracellular signaling in concentrations of 25-100 µM [12] [13] [14] . Considering the effects on cAMP levels obtained in the present study, we suggest that interpretation of results with genistein should be made with caution especially when combined with other cAMP-increasing agents.
In summary, the tyrosine kinase inhibitor genistein (50 µM) increases basal level of cAMP to the same extent as the unspecific PDE inhibitor IBMX (100 µM) in A549 human airway epithelial cells. Furthermore, genistein and IBMX potentiate forskolin-induced cAMP accumulation to the same extent. Thus, the use of genistein in studies on signaling transductions in the A549 cells may result in erroneous conclusions since increased cAMP may cause or contribute to the observed effects.
